Is This the Most Democratic Biotech Cap Table You’ve Ever Seen?

Only 9 Days Left to Invest at $3.00/Share, Raise Closes August 27 at 11:59 PM. 

Most biotech cap tables look like a Who’s Who of Venture Capital and private equity firms.

By the time you find out about it? The valuations are sky-high. The special preferences are locked in. And the best-case scenario for regular investors is… “leftovers.”

Not with Cytonics; this is one of the most democratic cap tables you’ll see in biotech… ever.

And the window to be part of it closes August 27.

This is the final chance to invest at the $3.00/share valuation, before potential future raises at higher prices and new terms.


Here’s What Makes Cytonics Different

• $25M+ raised without a single dime of venture capital
• 7,000+ individual investors, not institutions
• Clean, single-class stock; no special deals, no liquidation preferences
• Founders still own 18.9% of the company, and their CEO is on track for 10%... this is meaningful equity that keeps their incentives aligned with yours. Phase 1 completed, with CYT-108 entering the most value-creating stage of biotech: Phase 2

In other words, this isn’t a pitch deck of some pie-in-the-sky dream. It’s a clinical-stage drug development platform that thousands of retail investors already believe in.


Why This Structure Matters

When most biotechs exit:

• VCs get their money first, usually as a guaranteed multiple of their original investment
• Retail gets what’s left
• Founders get boxed out unless they negotiate like lawyers

Cytonics said Hell No to that.

Here, everyone plays by the same rules:

• No institutional preferences
• No backroom deals
• No second-tier investors

There’s a buyout, IPO, or licensing deal; you’re in the same boat as the insiders. Only 9 Days Left to Join at $3.00/Share

This is your final opportunity to:

• Get in before Phase 2 launches
• Own equity at a meaningful valuation
• Share the same upside as major shareholders and insiders
• Join a movement that’s rewriting how biotech is built

Future raises may come. But they won’t look like this.

Join 7,000+ investors before the window closes.